An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Trial Profile

An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Neuroblastoma; Paraganglioma; Pheochromocytoma
  • Focus Adverse reactions; Expanded access
  • Sponsors Jubilant DraxImage
  • Most Recent Events

    • 08 Aug 2012 Additional lead trial investigator identified as reported by Vanderbilt-Ingram Cancer Center.
    • 08 Aug 2012 Actual initiation date (6 Aug 2012) added as reported by Vanderbilt-Ingram Cancer Center.
    • 08 Aug 2012 New source identified and integrated (Vanderbilt-Ingram Cancer Center: VICCPED1249).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top